Brief: The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE (pegcetacoplan injection) for Geographic Atrophy

Apellis Pharmaceuticals

20/10/2023 13:18

Oct 20 (Reuters) - Apellis Pharmaceuticals Inc  APLS.O :
    * THE LANCET PUBLISHES 24-MONTH RESULTS FROM PHASE 3 STUDIES
OF
SYFOVRE® (PEGCETACOPLAN INJECTION) FOR GEOGRAPHIC ATROPHY (GA)
    * APELLIS PHARMACEUTICALS INC - SYFOVRE DEMONSTRATED
CLINICALLY
MEANINGFUL REDUCTIONS IN GA LESION GROWTH IN AS FEW AS SIX DOSES
PER YEAR

Source text for Eikon:  ID:nGNX8JhvQ3 
Further company coverage:  APLS.O 

 ((Reuters.Briefs@thomsonreuters.com;))